Oncotarget

Research Papers:

Activation of hERG3 channel stimulates autophagy and promotes cellular senescence in melanoma

Mathew Perez-Neut _, Lauren Haar, Vidhya Rao, Sreevidya Santha, Katherine Lansu, Basabi Rana, Walter K. Jones and Saverio Gentile

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:21991-22004. https://doi.org/10.18632/oncotarget.7831

Metrics: PDF 1904 views  |   HTML 3305 views  |   ?  


Abstract

Mathew Perez-Neut1, Lauren Haar1, Vidhya Rao1, Sreevidya Santha1, Katherine Lansu1, Basabi Rana1, Walter K. Jones1, Saverio Gentile1

1Department of Molecular Pharmacology & Therapeutics, Loyola University, Chicago, IL-60153, USA

Correspondence to:

Saverio Gentile, e-mail: [email protected]

Keywords: potassium channels, autophagy, hERG, senescence, melanoma

Received: January 12, 2016     Accepted: February 15, 2016     Published: March 01, 2016

ABSTRACT

Ion channels play a major factor in maintaining cellular homeostasis but very little is known about the role of these proteins in cancer biology. In this work we have discovered that, the Kv11.3 (hERG3) a plasma-membrane potassium channel plays a critical role in the regulation of autophagy in a cancer cell model. We have found that pharmacologic stimulation of the Kv11.3 channel with a small molecule activator, NS1643 induced autophagy via activation of an AMPK-dependent signaling pathway in melanoma cell line. In addition, we have found that NS1643 produced a strong inhibition of cell proliferation by activating a cellular senescence program. Furthermore, inhibition of autophagy via siRNA targeting AMPK or treatment with hydroxychloroquine an autophagy inhibitor activates apoptosis in NS1643-treated cells. Thus, we propose that, Kv11.3 is a novel mediator of autophagy, autophagy can be a survival mechanism contributing to cellular senescence, and that use of a combinatorial pharmacologic approach of Kv11.3 activator with inhibitors of autophagy represents a novel therapeutic approach against melanoma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7831